Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
381 stopped studies mapped to Malignant Kidney Neoplasm and descendants · 86% state a reason
Over the 381 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | Phase 1 / Phase 2 | withdrawn | Apr 25, 2019 | HealthPartners Institute | funding issues | Funding |
| NCT01355562 | Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney… | Phase 2 | withdrawn | May 18, 2011 | Loma Linda University | Primary Investigator is no longer employed at LLU as of 02/29/12. | Investigator |
| NCT00854022 | Genetic Susceptibility to Kidney Cancer | — | terminated | Mar 2, 2009 | Baylor College of Medicine | Funding ended | Funding |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT03943771 | Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to…(R3DP-A) | N/A | withdrawn | May 9, 2019 | University Hospital, Bordeaux | Schedule issue | Other (stated, no rule matched) |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating… | Phase 2 | withdrawn | May 2, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT03692338 | INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or…(INTERVAL) | N/A | terminated | Oct 2, 2018 | Duke University | Poor accrual | Enrollment / accrual |
| NCT00582790 | Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer | Phase 2 | terminated | Dec 28, 2007 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy… | Phase 1 / Phase 2 | terminated | Sep 11, 2009 | Celgene | MTD determined sub-optimal as efficacious treatment for renal cell carcinoma. | Other (stated, no rule matched) |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | Phase 2 | terminated | May 2, 2008 | National Cancer Institute (NCI) | A more highly selected protocol with ESO TCR opened for pts with melanoma | Other (stated, no rule matched) |
| NCT02795819 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | Phase 1 | terminated | Jun 10, 2016 | Virginia Commonwealth University | Study drug no longer being clinically developed by manufacturer | Drug supply |
| NCT01239342 | Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | Phase 2 | terminated | Nov 11, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01545817 | Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma(CATChEz) | Phase 2 | terminated | Mar 7, 2012 | Novartis Pharmaceuticals | As the therapeutic landscape in renal cell carcinoma is changing, it has become apparent that… | Other (stated, no rule matched) |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma… | Phase 1 / Phase 2 | terminated | May 19, 2015 | Fox Chase Cancer Center | IRB study closure facilitated by Investigator | Investigator |
| NCT01599754 | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients(ATLAS) | Phase 3 | terminated | May 16, 2012 | SFJ Pharma Ltd. II | Primary endpoint did not reach statistical significance | Other (stated, no rule matched) |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | N/A | withdrawn | Jan 24, 2018 | University of Southern California | No accrual | Enrollment / accrual |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal… | Phase 1 / Phase 2 | terminated | May 9, 2006 | AHS Cancer Control Alberta | Retirement of former Qualified Investigator and lack of resources to complete study. | Investigator |
| NCT01391130 | A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Jul 11, 2011 | Eli Lilly and Company | Study Terminated due to Insufficient Efficacy | Efficacy / futility |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 2, 2016 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | Phase 1 / Phase 2 | withdrawn | Apr 13, 2017 | William Grosh, MD | funding was withdrawn | Funding |
| NCT00538772 | An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell… | — | withdrawn | Oct 3, 2007 | Kim Chi | not stated | Not stated |
| NCT02428335 | Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib | — | withdrawn | Apr 28, 2015 | AHS Cancer Control Alberta | Insufficient financial resources to conduct research and complete trial. | Funding |
| NCT03528057 | Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy | N/A | withdrawn | May 17, 2018 | Northwestern University | Difficulty recruiting participants. | Enrollment / accrual |
| NCT02005614 | A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI… | N/A | terminated | Dec 9, 2013 | Yale University | Unable to recruit patients. | Enrollment / accrual |
| NCT03185182 | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma(RCCSCAN) | Phase 2 | terminated | Jun 14, 2017 | Region Skane | Due to "early stopping rule" as defined in the study protocol | Other (stated, no rule matched) |
| NCT01195649 | Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or… | — | terminated | Sep 6, 2010 | Bayer | not stated | Not stated |
| NCT00727532 | Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | N/A | terminated | Aug 4, 2008 | Northwestern University | Low Accrual | Enrollment / accrual |
| NCT00923390 | Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell… | Phase 1 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01198158 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer… | Phase 3 | terminated | Sep 9, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02867332 | PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. | Phase 1 | withdrawn | Aug 15, 2016 | Peking University | No funding | Funding |
| NCT01502228 | PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma | N/A | terminated | Dec 30, 2011 | Indiana University | No further funding | Funding |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | Phase 1 | terminated | May 4, 2010 | Eli Lilly and Company | Primary objective has been met; safety and pharmacokinetics have been characterized. | Safety / toxicity |
| NCT03323710 | Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell… | Phase 2 | withdrawn | Oct 27, 2017 | Military Institute od Medicine National Research Institute | Poor patient recruitment. | Enrollment / accrual |
| NCT01441414 | PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated… | Phase 2 | terminated | Sep 27, 2011 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT02026960 | RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal… | N/A | terminated | Jan 3, 2014 | Duke University | The sponsor's clinical program for the agent used in this study was discontinued. | Other (stated, no rule matched) |
| NCT01740154 | Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer | N/A | terminated | Dec 4, 2012 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT00540969 | Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone… | Phase 3 | terminated | Oct 8, 2007 | Alliance for Clinical Trials in Oncology | Low accrual | Enrollment / accrual |
| NCT00126659 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | Phase 2 | terminated | Aug 4, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or… | Phase 3 | withdrawn | Oct 3, 2018 | Hoffmann-La Roche | In the context of the ongoing evaluation of our data, we have determined that there is no need to… | Safety / toxicity |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination…(RENALVax-2) | Phase 2 | withdrawn | Jul 21, 2017 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | No patients enrolled due to change in standard practice | Enrollment / accrual |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | Phase 2 | terminated | Feb 1, 2016 | Washington University School of Medicine | Low accrual, funding withdrawn by AstraZeneca, and change in clinical practice | Enrollment / accrual |
| NCT02560012 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | Phase 2 | terminated | Sep 25, 2015 | The University of Texas Health Science Center, Houston | Loss of laboratory performing molecular analysis | Other (stated, no rule matched) |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus… | Phase 2 | withdrawn | May 5, 2016 | Bristol-Myers Squibb | Insufficient enrollment | Enrollment / accrual |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT01453465 | Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or… | — | withdrawn | Oct 17, 2011 | Children's Oncology Group | not stated | Not stated |
| NCT01642095 | Studying Biomarkers in Samples From Younger Patients With Kidney Cancer | — | withdrawn | Jul 17, 2012 | Children's Oncology Group | not stated | Not stated |
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell… | Phase 1 | terminated | Mar 11, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT00089102 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or… | Phase 2 | terminated | Aug 5, 2004 | Medical University of South Carolina | Low accrual | Enrollment / accrual |
| NCT00090870 | PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With… | Phase 2 | terminated | Sep 8, 2004 | Medical University of South Carolina | Pharmaceutical collaborator pulled funding. | Funding |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | Phase 1 / Phase 2 | terminated | Apr 22, 2015 | Western Regional Medical Center | Investigator no longer at site to enroll patients or write up data | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 7, 2020source: clinicaltrials